Stevanato Group S.p.A. (STVN) – What Are Researchers Saying About This Stock?

Stevanato Group S.p.A. (NYSE:STVN) has received an average recommendation of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company.

STVN has been the topic of a number of recent research reports. Weiss Ratings raised Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. UBS Group began coverage on shares of Stevanato Group in a report on Wednesday, September 9th. They issued a “neutral” rating and a $23.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Stevanato Group in a research report on Wednesday, October 7th. They set a “hold” rating for the company.

Stevanato Group Trading Down 4.6%

NYSE STVN opened at €19.30 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.08 and a current ratio of 1.61. The company has a market capitalization of $5.84 billion, a price-to-earnings ratio of 34.46, a price-to-earnings-growth ratio of 1.67 and a beta of 0.78. The company’s 50-day simple moving average is €20.58 and its two-hundred day simple moving average is €18.14. Stevanato Group has a one year low of €12.89 and a one year high of €27.00.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported €0.14 EPS for the quarter, missing the consensus estimate of €0.15 by (€0.01). Stevanato Group had a net margin of 10.99% and a return on equity of 10.43%. The business had revenue of €302.00 million during the quarter. Equities analysts forecast that Stevanato Group will post 0.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Elisabetta Magistretti sold 2,045 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €41,084.05. Following the transaction, the director owned 2,930 shares in the company, valued at €58,863.70. This represents a 41.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mauro Stocchi sold 13,649 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of €21.50, for a total transaction of €293,453.50. Following the completion of the transaction, the insider directly owned 400,000 shares of the company’s stock, valued at €8,600,000. The trade was a 3.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 21,926 shares of company stock valued at $459,738. 0.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Stevanato Group

A number of large investors have recently made changes to their positions in STVN. Wellington Management Group LLP acquired a new position in shares of Stevanato Group in the 2nd quarter valued at $22,621,000. Ranger Investment Management L.P. acquired a new stake in Stevanato Group during the 2nd quarter worth about $21,438,000. Conestoga Capital Advisors LLC lifted its position in Stevanato Group by 7.6% during the 1st quarter. Conestoga Capital Advisors LLC now owns 8,491,751 shares of the company’s stock worth $116,762,000 after acquiring an additional 602,050 shares during the period. Fenimore Asset Management Inc acquired a new stake in Stevanato Group during the 3rd quarter worth about $12,212,000. Finally, Confluence Investment Management LLC purchased a new stake in Stevanato Group during the 2nd quarter valued at about $6,062,000.

About Stevanato Group

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.